Scinai Immunotherapeutics Reports Promising Psoriasis Model Results
Ticker: SCNI · Form: 6-K · Filed: Jul 15, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: biotech, clinical-trial-update, psoriasis
Related Tickers: SCNI
TL;DR
Scinai (SCNI) shows good results in psoriasis model, could be a win for skin disease treatments.
AI Summary
On July 15, 2024, Scinai Immunotherapeutics Ltd. announced promising in-vivo proof-of-concept results for its psoriatic human skin model. The company, formerly known as BiondVax Pharmaceuticals Ltd., is a biotechnology firm focused on biological products.
Why It Matters
Positive results in a psoriasis model could indicate potential for new treatments for this common skin condition, impacting millions of patients.
Risk Assessment
Risk Level: medium — While promising, these are early-stage in-vivo results, and further clinical trials are needed to confirm efficacy and safety in humans.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
- July 15, 2024 (date) — Date of press release
FAQ
What specific type of psoriatic human skin model did Scinai Immunotherapeutics use?
The filing states that Scinai Immunotherapeutics announced promising results in an 'in-vivo proof-of-concept psoriatic human skin model'.
When did Scinai Immunotherapeutics issue the press release regarding these results?
The press release announcing the promising results was issued on July 15, 2024.
What was Scinai Immunotherapeutics' former company name?
Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.
Under which SEC form is this report filed?
This report is filed under Form 6-K, a Report of Foreign Private Issuer.
What is the primary business of Scinai Immunotherapeutics Ltd. according to the filing?
According to the filing, Scinai Immunotherapeutics Ltd. is involved in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Stats: 250 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-07-15 11:02:23
Filing Documents
- ea0209426-6k_scinai.htm (6-K) — 12KB
- ea020942601ex99-1_scinai.htm (EX-99.1) — 19KB
- 0001213900-24-061221.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: July 15, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2